LivaNova (NASDAQ:LIVN) Downgraded to Buy Rating by StockNews.com

LivaNova (NASDAQ:LIVN) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other equities analysts have also recently issued reports on LIVN. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group assumed coverage on LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target on the stock. Mizuho lowered their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Robert W. Baird lifted their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Stifel Nicolaus lifted their price target on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Stock Down 0.4 %

Shares of LivaNova stock opened at $52.10 on Friday. The business’s fifty day moving average price is $51.67 and its two-hundred day moving average price is $52.98. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market capitalization of $2.83 billion, a P/E ratio of 124.05 and a beta of 1.01. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47.

Hedge Funds Weigh In On LivaNova

A number of hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of LivaNova in the 3rd quarter worth $550,000. Point72 DIFC Ltd grew its holdings in shares of LivaNova by 75,799.6% in the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock worth $9,531,000 after acquiring an additional 181,161 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after acquiring an additional 806,374 shares during the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of LivaNova during the third quarter valued at $1,949,000. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of LivaNova by 19.5% during the third quarter. Parkman Healthcare Partners LLC now owns 101,729 shares of the company’s stock valued at $5,345,000 after buying an additional 16,570 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.